Additional data file 2. Clinicopathological characteristics of ovarian cancer patients (

Keywords Breast and ovarian cancer Male BRCA 1/2 mutation carriers Male fear of developing cancer Men and genetic counselling Men’s

Clinicopathological variables and molecular markers in type 1 and type 2 endometrial carcinoma16,47,49,55 Clinicopathological variable Type 1 Type 2

Patients (n = 300) over the age of 18 years, with a recent diagnosis of breast cancer, colorectal cancer, lymphoma, prostate cancer or testicle cancer and scheduled for ad-

LM, FLT3 length mutation; M, NPM1 mutation; ND, not determined, Chemo, Chemotherapy consisted of three days with idarubicin (I) or daunorubicin (D), and concomitantly start up

(3) Denoted “TCGA”: Primary ovarian cancer samples (n=342, serous ovarian cancers, median 58 years at diagnosis; 316 received Carboplatin-based chemotherapy), analyzed

** 98 and 59 patients received Carboplatin in combination with Cyclophosphamide and Paclitaxel, respectively; 10 and 8 patients received Cisplatin in combination with

Patients are stratified into patients who did receive Cisplatin-based chemotherapy (n=26) or received Carboplatin (Carboplatin-Monotherapy or combination

* the log-rank P value (Kaplan Meier statistics; comparing 5 year survival between Carboplatin and Cisplatin treated patients)